Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32449174,time to maximum concentrations,"Ravulizumab PK parameters were numerically comparable in both studies; the median time to maximum concentrations ranged from 2·3 to 2·8 and 2·3 to 2·6 h in studies 301 and 302, respectively.","Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32449174/),h,2·3 to 2·8,25452,DB01257,Eculizumab
,32449174,time to maximum concentrations,"Ravulizumab PK parameters were numerically comparable in both studies; the median time to maximum concentrations ranged from 2·3 to 2·8 and 2·3 to 2·6 h in studies 301 and 302, respectively.","Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32449174/),h,2·3 to 2·6,25453,DB01257,Eculizumab
,32449174,terminal elimination half-life,"For ravulizumab, the mean (SD) post hoc terminal elimination half-life was 49·7 (8·9) days.","Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32449174/),d,49·7,25454,DB01257,Eculizumab
<,32449174,Serum free C5 concentrations,Serum free C5 concentrations <0·5 µg/ml were achieved after the first ravulizumab dose and sustained throughout treatment in both studies.,"Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32449174/),[μg] / [ml],0·5,25455,DB01257,Eculizumab
<,32449174,free C5 concentrations,"In a minority of patients, free C5 concentrations <0·5 µg/ml were not consistently achieved with eculizumab in either study.","Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32449174/),[μg] / [ml],0·5,25456,DB01257,Eculizumab
,33118186,trough concentration,Recent studies reported an overexposure in many patients when considering a target trough concentration range of 50-100 mg/L.,Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118186/),[mg] / [l],50-100,38208,DB01257,Eculizumab
above,33118186,trough concentration,"In the first phase, we developed a pharmacokinetic population model using data from 40 patients and identified patients for whom a 1-week lengthening of interval between infusions would lead to a trough concentration above 100 mg/L.",Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118186/),[mg] / [l],100,38209,DB01257,Eculizumab
above,33118186,trough concentration,"In the second phase of the study, a 1-week lengthening of interval between infusions was performed in 15 patients whose trough concentration at the next visit was predicted with a Bayesian model to be above 100 mg/L.",Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118186/),[mg] / [l],100,38210,DB01257,Eculizumab
over,33118186,trough concentrations,"After interval extension, 10 patients (67%) presented measured trough concentrations over 100 mg/L.",Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33118186/),[mg] / [l],100,38211,DB01257,Eculizumab
>,31921730,trough concentration,Pharmacokinetic simulation suggested that the 2- and 3-week interval regimen could be sufficient to achieve an efficient trough concentration (>100 μg/mL).,Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31921730/),[μg] / [ml],100,43820,DB01257,Eculizumab
,26456258,clearance,"In the PK analysis, we found significant interpatient variability in eculizumab clearance, ranging from 16 to 237 mL/hr/70 kg in the induction phase.",Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456258/),[ml] / [70·h·kg],16 to 237,89766,DB01257,Eculizumab
,26456258,Overall survival,"Overall survival was significantly higher in treated subjects compared with untreated patients (56% versus 9%, P = .003).",Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456258/),%,56,89767,DB01257,Eculizumab
,26456258,Overall survival,"Overall survival was significantly higher in treated subjects compared with untreated patients (56% versus 9%, P = .003).",Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26456258/),%,9,89768,DB01257,Eculizumab
,24497537,IC50,Both compounds demonstrated dose-dependent inhibition of hemolysis with IC50 ∼4 µM and full inhibition at 6 µM.,Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24497537/),μM,∼4,133921,DB01257,Eculizumab
>,24497537,elimination half-life,A single intravenous injection of PEG-Cp40 resulted in a prolonged elimination half-life of >5 days but may potentially affect the plasma levels of C3.,Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24497537/),d,5,133922,DB01257,Eculizumab
,33047216,half-maximal effective dose (ED50),"The dose-response relationship, described by an inhibitory sigmoid maximum effect (Emax) model, estimated half-maximal effective dose (ED50) of 14.0 mg and maximum C5 reduction of 99% at 600 mg.","Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33047216/),mg,14.0,134528,DB01257,Eculizumab
>,26337866,Trough eculizumab concentrations,"Trough eculizumab concentrations were >50 µg/mL in 9/9, >100 µg/mL in 8/9, and >300 µg/mL in 5/9 of patients.",Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337866/),[μg] / [ml],50,202539,DB01257,Eculizumab
>,26337866,Trough eculizumab concentrations,"Trough eculizumab concentrations were >50 µg/mL in 9/9, >100 µg/mL in 8/9, and >300 µg/mL in 5/9 of patients.",Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337866/),[μg] / [ml],100,202540,DB01257,Eculizumab
>,26337866,Trough eculizumab concentrations,"Trough eculizumab concentrations were >50 µg/mL in 9/9, >100 µg/mL in 8/9, and >300 µg/mL in 5/9 of patients.",Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337866/),[μg] / [ml],300,202541,DB01257,Eculizumab
,26337866,elimination half-life,"Pharmacokinetic modeling showed that the elimination half-life varied greatly, with an increase from 7.8 d in a patient weighing 100 kg to 19.5 d in a 40 kg patient.",Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337866/),d,7.8,202542,DB01257,Eculizumab
,26337866,elimination half-life,"Pharmacokinetic modeling showed that the elimination half-life varied greatly, with an increase from 7.8 d in a patient weighing 100 kg to 19.5 d in a 40 kg patient.",Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337866/),d,19.5,202543,DB01257,Eculizumab
,28766381,LOD,"The LOD, LLOQ and ULOQ were 0.091, 0.25 and 82.35 mg/l, respectively.",Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766381/),[mg] / [l],0.091,212269,DB01257,Eculizumab
,28766381,LOD,"The LOD, LLOQ and ULOQ were 0.091, 0.25 and 82.35 mg/l, respectively.",Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766381/),[mg] / [l],0.25,212270,DB01257,Eculizumab
,28766381,LOD,"The LOD, LLOQ and ULOQ were 0.091, 0.25 and 82.35 mg/l, respectively.",Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28766381/),[mg] / [l],82.35,212271,DB01257,Eculizumab
